Company CVAbout Neuland Laboratories Ltd 
Neuland Laboratories Ltd
Small Cap
Pharmaceuticals & Biotechnology
Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao. The Company is engaged in manufacturing and selling of bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. Neuland Drugs & Pharmaceuticals Pvt. Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992. NLL manufactures bulk drugs.
Company Coordinates
Company Details
11 Th Floor Phoenix IVY Buildi, Plot No 573A-III Road No 82 Hyderabad Telangana : 500035
Registrar Details
Karvy Computershare Pvt Ltd., Karvy Selenium, Tower-B Plot No 31 & 32, Survey No 116/22, 115/24, 115/25, Financial District, Nanakramguda, Serilingampally, Mandal Ranga Reddy Dist, Hyderabad
Capital StructureCapital Structure
Present Equity Capital
INR 12.83 Cr
Number of Shares
1.28 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
23-May-2018
1.28
12.83
1675000
10
QIB Equity Shares
24-Oct-2016
88.84
8.88
1000
10
ESOP
24-Oct-2016
88.84
8.88
1000
10
ESOP
13-Aug-2014
88.83
8.88
1225276
10
Right Issues
13-Aug-2014
88.83
8.88
1225276
10
Right Issues
17-Jul-2014
76.58
7.66
2300
10
ESOP
17-Jul-2014
76.58
7.66
2300
10
ESOP
21-Jan-2014
76.56
7.66
10700
10
ESOP
21-Jan-2014
76.56
7.66
10700
10
ESOP
21-Mar-2012
76.45
7.64
2248523
10
Right Issues
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Non Institution
Pledged Promoter Holdings
None
Mutual Funds
Held by 28 Schemes (9.78%)
FIIs
Held by 171 FIIs (20.6%)
Promoter with highest holding
Davuluri Ownership Trust (dr. Davuluri Ramamohan Rao, Mr. Davuluri Sucheth Rao And Mr. Davuluri Saha (25.98%)
Highest Public shareholder
Malabar India Fund Limited (5.76%)
Individual Investors Holdings
24.72%
Board of Directors
Management
Designation
Remuneration
D R Rao
Executive Chairman
6.0 cr
H Dhanrajgir
Independent Director
16.4 lacs
P V Maiya
Independent Director
19.2 lacs
Christopher M Cimarusti
Director
17.5 lacs
D Sucheth Rao
Vice Chairman & CEO
5.75 cr
D Saharsh Rao
Vice Chairman & M.D.
5.75 cr
Sarada Bhamidipati
Company Sec. & Compli. Officer
0
Bharati Rao
Independent Director
22.1 lacs
Nirmala Murthy
Independent Director
21.1 lacs
Homi Rustam Khusrokhan
Independent Director
21.9 lacs
Prasad R Menon
Independent Director
17.4 lacs
Sugata Sircar
Independent Director
0
Pallavi Joshi Bakhru
Independent Director
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Bulk Drugs
622.75
93.39%
Export Incentives
20.85
3.13%
Services
15.57
2.33%
Bulk Drugs
Bulk Drugs
Export Incentives
Export Incentives
Services
Services
Stock DNARevenue and Profits:
Net Sales:
514 Cr
(Quarterly Results - Sep 2025)
Net Profit:
97 Cr
Pharmaceuticals & Biotechnology
INR 21,398 Cr (Small Cap)
111.00
34
0.07%
0.06
12.09%
13.38
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
